Q4 EPS Estimate for Fennec Pharmaceuticals Raised by Analyst

Fennec Pharmaceuticals Inc. (TSE:FRX) – Wedbush increased their Q4 2024 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research report issued on Sunday, December 22nd. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $1.88 per share for the quarter, up from their previous forecast of ($0.24). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.16) EPS, Q4 2025 earnings at $0.66 EPS and FY2025 earnings at $0.66 EPS.

Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$8.93 on Wednesday. The business’s 50-day moving average price is C$7.19 and its 200-day moving average price is C$7.67. The firm has a market capitalization of C$244.32 million, a PE ratio of 89.30 and a beta of 0.25. Fennec Pharmaceuticals has a 12 month low of C$5.65 and a 12 month high of C$15.43. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68.

Insider Activity at Fennec Pharmaceuticals

In related news, Director Rostislav Christov Raykov purchased 25,000 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were acquired at an average cost of C$3.87 per share, with a total value of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the stock in a transaction on Monday, November 18th. The stock was bought at an average price of C$3.43 per share, with a total value of C$54,248.88. In the last 90 days, insiders have acquired 41,612 shares of company stock valued at $157,868. Insiders own 16.20% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.